Bio One Capital Pte Ltd, a subsidiary of EDB Investments (EDBI), is dedicated to investments in the Biomedical Sciences industry. Biomedical Sciences (BMS) is a key economic driver and an important pillar of Singapore’s diverse economy. With over US$790 million currently under management, Bio*One Capital is actively investing their fourth fund, Biomedical Sciences Investments Fund (BMSIF). Key sectors of interest are therapeutics and therapeutics services, medical technology and healthcare services.
| Company | Date | Round | Size | Participants |
| Amaranth Medical Inc | 6/13 | Series B | $25M | 3 |
| OptiMedica | 11/12 | Venture Round | $35M | 4 |
| TriReme Medical | 10/10 | Series D | $17M | 3 |
| MerLion Pharmaceuticals | 10/10 | Series C | $7M | 3 |
| Artisan Pharma | 7/10 | Series C | $3M | 5 |
| Artisan Pharma | 3/10 | Series B | $22M | 4 |
| FORMA Therapeutics | 12/09 | Series B | $3M | 3 |
| FORMA Therapeutics | 12/09 | Series B | $25.5M | 3 |
| Inviragen | 10/09 | Series A | $15M | 4 |
| S*Bio | 10/08 | Venture Round | $26M | 6 |
| Pelikan Technologies | 12/07 | Series F | $69M | 3 |
| Fluidigm | 1/07 | Series E | $17M | 10 |
| RenaMed Biologics | 9/06 | Venture Round | $40M | 9 |
| Artisan Pharma | 9/06 | Series A | $39M | 5 |
| Codexis | 8/06 | Series D | $37M | 5 |
| Takeda Cambridge | 7/06 | Series D | $13M | 3 |
| Takeda Cambridge | 1/05 | Venture Round | $9.38M | 3 |
